WCM Investment Management LLC Lowers Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

WCM Investment Management LLC cut its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 6.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 145,349 shares of the biopharmaceutical company’s stock after selling 9,326 shares during the period. WCM Investment Management LLC owned about 0.16% of Ultragenyx Pharmaceutical worth $7,911,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of Ultragenyx Pharmaceutical by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 8,700,007 shares of the biopharmaceutical company’s stock valued at $406,203,000 after purchasing an additional 26,575 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Ultragenyx Pharmaceutical by 3.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,568,873 shares of the biopharmaceutical company’s stock valued at $166,632,000 after purchasing an additional 120,175 shares during the last quarter. Clearbridge Investments LLC grew its holdings in shares of Ultragenyx Pharmaceutical by 0.7% during the 1st quarter. Clearbridge Investments LLC now owns 2,400,854 shares of the biopharmaceutical company’s stock valued at $112,096,000 after purchasing an additional 17,362 shares during the last quarter. Federated Hermes Inc. raised its position in Ultragenyx Pharmaceutical by 8.7% in the 2nd quarter. Federated Hermes Inc. now owns 2,107,025 shares of the biopharmaceutical company’s stock worth $86,599,000 after purchasing an additional 168,345 shares during the period. Finally, Millennium Management LLC lifted its stake in Ultragenyx Pharmaceutical by 103.8% in the second quarter. Millennium Management LLC now owns 1,850,734 shares of the biopharmaceutical company’s stock worth $76,065,000 after purchasing an additional 942,529 shares during the last quarter. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Trading Up 0.7 %

Ultragenyx Pharmaceutical stock opened at $50.73 on Tuesday. Ultragenyx Pharmaceutical Inc. has a 12 month low of $34.06 and a 12 month high of $60.37. The business’s fifty day simple moving average is $54.94 and its two-hundred day simple moving average is $48.27. The company has a market capitalization of $4.68 billion, a price-to-earnings ratio of -7.84 and a beta of 0.58.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.45) by $0.05. The business had revenue of $139.49 million during the quarter, compared to analysts’ expectations of $135.28 million. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. The business’s revenue for the quarter was up 42.3% compared to the same quarter last year. During the same period in the previous year, the company earned ($2.23) earnings per share. On average, equities research analysts predict that Ultragenyx Pharmaceutical Inc. will post -6.21 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on RARE shares. Royal Bank of Canada restated an “outperform” rating and set a $77.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 6th. Canaccord Genuity Group lifted their target price on shares of Ultragenyx Pharmaceutical from $109.00 to $121.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. HC Wainwright increased their price target on shares of Ultragenyx Pharmaceutical from $82.00 to $95.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. TD Cowen increased their target price on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Finally, The Goldman Sachs Group upped their price target on Ultragenyx Pharmaceutical from $67.00 to $76.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Two equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $86.69.

Insiders Place Their Bets

In related news, CFO Howard Horn sold 7,465 shares of the stock in a transaction on Thursday, October 10th. The stock was sold at an average price of $52.76, for a total transaction of $393,853.40. Following the sale, the chief financial officer now directly owns 92,301 shares of the company’s stock, valued at $4,869,800.76. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, CEO Emil D. Kakkis sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $55.85, for a total transaction of $1,117,000.00. Following the completion of the sale, the chief executive officer now directly owns 2,223,985 shares in the company, valued at approximately $124,209,562.25. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Howard Horn sold 7,465 shares of the company’s stock in a transaction on Thursday, October 10th. The stock was sold at an average price of $52.76, for a total value of $393,853.40. Following the completion of the sale, the chief financial officer now owns 92,301 shares of the company’s stock, valued at $4,869,800.76. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 27,556 shares of company stock valued at $1,515,967. Corporate insiders own 5.80% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.